Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tbo-filgrastim for Stem Cell Mobilization in Healthy Donors
NCT03029000Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of granisetron in stem cell mobilization, sponsored by Teva Pharmaceutical Industries Ltd.. Started Aug 2017; status: terminated.
02
Drugs
granisetron
03
Conditions
stem cell mobilization
Beyond the preview
Go deeper on NCT03029000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029000.